vs
Side-by-side financial comparison of Cushman & Wakefield Ltd. (CWK) and GE HealthCare (GEHC). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $2.9B, roughly 2.0× Cushman & Wakefield Ltd.). GE HealthCare runs the higher net margin — 10.3% vs -0.8%, a 11.1% gap on every dollar of revenue. On growth, Cushman & Wakefield Ltd. posted the faster year-over-year revenue change (10.8% vs 7.1%). Over the past eight quarters, Cushman & Wakefield Ltd.'s revenue compounded faster (15.5% CAGR vs 10.7%).
Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
CWK vs GEHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $5.7B |
| Net Profit | $-22.4M | $588.0M |
| Gross Margin | — | 39.7% |
| Operating Margin | 6.1% | 14.5% |
| Net Margin | -0.8% | 10.3% |
| Revenue YoY | 10.8% | 7.1% |
| Net Profit YoY | -119.8% | -18.4% |
| EPS (diluted) | $-0.10 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $5.7B | ||
| Q3 25 | $2.6B | $5.1B | ||
| Q2 25 | $2.5B | $5.0B | ||
| Q1 25 | $2.3B | $4.8B | ||
| Q4 24 | $2.6B | $5.3B | ||
| Q3 24 | $2.3B | $4.9B | ||
| Q2 24 | $2.3B | $4.8B | ||
| Q1 24 | $2.2B | $4.7B |
| Q4 25 | $-22.4M | $588.0M | ||
| Q3 25 | $51.4M | $446.0M | ||
| Q2 25 | $57.3M | $486.0M | ||
| Q1 25 | $1.9M | $564.0M | ||
| Q4 24 | $112.9M | $721.0M | ||
| Q3 24 | $33.7M | $470.0M | ||
| Q2 24 | $13.5M | $428.0M | ||
| Q1 24 | $-28.8M | $374.0M |
| Q4 25 | — | 39.7% | ||
| Q3 25 | — | 38.7% | ||
| Q2 25 | — | 39.6% | ||
| Q1 25 | — | 42.1% | ||
| Q4 24 | — | 42.8% | ||
| Q3 24 | — | 41.7% | ||
| Q2 24 | — | 41.4% | ||
| Q1 24 | — | 40.9% |
| Q4 25 | 6.1% | 14.5% | ||
| Q3 25 | 4.1% | 12.7% | ||
| Q2 25 | 4.9% | 13.1% | ||
| Q1 25 | 2.0% | 13.2% | ||
| Q4 24 | 6.6% | 15.1% | ||
| Q3 24 | 3.2% | 13.9% | ||
| Q2 24 | 3.1% | 12.6% | ||
| Q1 24 | 0.9% | 11.6% |
| Q4 25 | -0.8% | 10.3% | ||
| Q3 25 | 2.0% | 8.7% | ||
| Q2 25 | 2.3% | 9.7% | ||
| Q1 25 | 0.1% | 11.8% | ||
| Q4 24 | 4.3% | 13.6% | ||
| Q3 24 | 1.4% | 9.7% | ||
| Q2 24 | 0.6% | 8.8% | ||
| Q1 24 | -1.3% | 8.0% |
| Q4 25 | $-0.10 | $1.28 | ||
| Q3 25 | $0.22 | $0.98 | ||
| Q2 25 | $0.25 | $1.06 | ||
| Q1 25 | $0.01 | $1.23 | ||
| Q4 24 | $0.49 | $1.58 | ||
| Q3 24 | $0.14 | $1.02 | ||
| Q2 24 | $0.06 | $0.93 | ||
| Q1 24 | $-0.13 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $784.2M | $4.5B |
| Total DebtLower is stronger | $2.7B | $10.0B |
| Stockholders' EquityBook value | $2.0B | $10.4B |
| Total Assets | $7.7B | $36.9B |
| Debt / EquityLower = less leverage | 1.40× | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $784.2M | $4.5B | ||
| Q3 25 | $634.4M | $4.0B | ||
| Q2 25 | $618.2M | $3.7B | ||
| Q1 25 | $623.2M | $2.5B | ||
| Q4 24 | $793.3M | $2.9B | ||
| Q3 24 | $775.4M | $3.5B | ||
| Q2 24 | $567.3M | $2.0B | ||
| Q1 24 | $553.5M | $2.6B |
| Q4 25 | $2.7B | $10.0B | ||
| Q3 25 | $2.8B | $10.3B | ||
| Q2 25 | $3.0B | $10.3B | ||
| Q1 25 | $3.0B | $8.8B | ||
| Q4 24 | $3.0B | $9.0B | ||
| Q3 24 | $3.1B | $10.3B | ||
| Q2 24 | $3.1B | $9.2B | ||
| Q1 24 | $3.2B | $9.3B |
| Q4 25 | $2.0B | $10.4B | ||
| Q3 25 | $2.0B | $10.0B | ||
| Q2 25 | $1.9B | $9.7B | ||
| Q1 25 | $1.8B | $9.2B | ||
| Q4 24 | $1.8B | $8.4B | ||
| Q3 24 | $1.7B | $8.3B | ||
| Q2 24 | $1.6B | $7.8B | ||
| Q1 24 | $1.6B | $7.4B |
| Q4 25 | $7.7B | $36.9B | ||
| Q3 25 | $7.7B | $36.1B | ||
| Q2 25 | $7.6B | $35.5B | ||
| Q1 25 | $7.4B | $33.6B | ||
| Q4 24 | $7.5B | $33.1B | ||
| Q3 24 | $7.5B | $33.9B | ||
| Q2 24 | $7.3B | $31.9B | ||
| Q1 24 | $7.5B | $32.2B |
| Q4 25 | 1.40× | 0.96× | ||
| Q3 25 | 1.45× | 1.03× | ||
| Q2 25 | 1.57× | 1.06× | ||
| Q1 25 | 1.70× | 0.95× | ||
| Q4 24 | 1.73× | 1.06× | ||
| Q3 24 | 1.81× | 1.24× | ||
| Q2 24 | 1.91× | 1.18× | ||
| Q1 24 | 1.96× | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $257.3M | — |
| Free Cash FlowOCF − Capex | $234.3M | — |
| FCF MarginFCF / Revenue | 8.0% | — |
| Capex IntensityCapex / Revenue | 0.8% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $293.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $257.3M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $9.6M | $94.0M | ||
| Q1 25 | $-162.0M | $250.0M | ||
| Q4 24 | $115.2M | — | ||
| Q3 24 | $196.1M | — | ||
| Q2 24 | $21.8M | $-119.0M | ||
| Q1 24 | $-125.1M | $419.0M |
| Q4 25 | $234.3M | — | ||
| Q3 25 | $225.0M | — | ||
| Q2 25 | $300.0K | $8.0M | ||
| Q1 25 | $-166.6M | $98.0M | ||
| Q4 24 | $105.9M | — | ||
| Q3 24 | $186.7M | — | ||
| Q2 24 | $10.0M | $-183.0M | ||
| Q1 24 | $-135.6M | $274.0M |
| Q4 25 | 8.0% | — | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | -7.3% | 2.1% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | 0.4% | -3.8% | ||
| Q1 24 | -6.2% | 5.9% |
| Q4 25 | 0.8% | 2.4% | ||
| Q3 25 | 0.4% | 2.1% | ||
| Q2 25 | 0.4% | 1.7% | ||
| Q1 25 | 0.2% | 3.2% | ||
| Q4 24 | 0.4% | 1.9% | ||
| Q3 24 | 0.4% | 1.9% | ||
| Q2 24 | 0.5% | 1.3% | ||
| Q1 24 | 0.5% | 3.1% |
| Q4 25 | — | — | ||
| Q3 25 | 4.58× | — | ||
| Q2 25 | 0.17× | 0.19× | ||
| Q1 25 | -85.26× | 0.44× | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 5.82× | — | ||
| Q2 24 | 1.61× | -0.28× | ||
| Q1 24 | — | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWK
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.8B | 61% |
| Other | $1.1B | 39% |
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
